Placebo (Normal saline solution)

DRUG4 trials

Sponsors

Innate Pharma, ImmuneMed, Inc.

Conditions

Acute Myeloid LeukemiaCOVID-19

Phase 2

Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)

CompletedNCT01687387

Innate PharmaAcute Myeloid Leukemia

Start: 2012-10-31End: 2016-11-17Updated: 2019-02-08

Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia

CompletedNCT04676971

ImmuneMed, Inc.COVID-19

Start: 2020-12-11End: 2021-10-28Updated: 2021-12-01

Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia

CompletedNCT04679415

ImmuneMed, Inc.COVID-19

Start: 2020-12-17End: 2021-08-19Updated: 2024-02-15

Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

TerminatedNCT04679350

ImmuneMed, Inc.COVID-19

Start: 2021-03-18End: 2022-12-30Updated: 2024-02-15

Related Papers

Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Blood2017-12-0739 citations